51³ΙΘΛΆ―Βώ

Meeting Coverage

ESMO

European Society for Medical Oncology

Rucaparib-Nivolumab Maintenance Not the Answer in Newly Diagnosed Ovarian Cancer

Poorer survival outcomes plus more toxicity versus rucaparib alone

ESMO over a photo of Fira Barcelona Gran Via in Barcelona, Spain.

Latest ESMO Meeting Coverage

Novel Agent Effective for Cancer Wasting Disorder

Cancer patients with cachexia added needed pounds with GDF-15 antibody

September 18, 2024
Lymphedema Risk No Higher With 3-Week RT Regimen in Early Breast Cancer

"Nodal radiotherapy for breast cancer no longer needs 5 weeks," researcher says

September 17, 2024
Survival Win for Pembrolizumab in Early Triple-Negative Breast Cancer

Absolute difference of 4.9% at 5 years, including a benefit for patients who did not achieve pCR

September 17, 2024
Cabozantinib Improves PFS for Advanced Neuroendocrine Tumors

Potential new option for patients with previously treated extrapancreatic or pancreatic NETs

September 17, 2024
Win for Perioperative Durvalumab in Muscle-Invasive Bladder Cancer

Results "practice-changing," says expert

September 16, 2024
Another Possible Treatment Option for Intermediate-Stage Liver Cancer

Adding lenvatinib, pembrolizumab to TACE significantly improved PFS, numerically improved OS

September 16, 2024
Radionuclide-Containing Combo Slows Metastatic Prostate Cancer, Improves Survival

Hazards for radiographic PFS, OS reduced by 31% with enzalutamide plus Ra-223

September 15, 2024
Retifanlimab-Chemo Combo Boosts PFS in Advanced Squamous Cell Anal Cancer

POD1UM-303/InterAACT 2 data also trend in the direction of better overall survival

September 15, 2024
No Survival Gain With Preoperative CRT Plus Perioperative Chemo for Gastric Cancer

But combination may be appropriate for shrinking tumors before surgery

September 14, 2024
Another Win for Antibody-Drug Conjugate in HER2+ Breast Cancer With Brain Mets

Second-line T-DXd best option in patients with and without intracranial activity, experts says

September 14, 2024
No PFS Benefit With Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma

Data support that ICI rechallenge should be discouraged in patients with advanced RCC

September 13, 2024
Neoadjuvant Cemiplimab Shows Potential as an Option for Cutaneous SCC

Follow-up results from phase II study show 12-month EFS rate of 89% in stage II-IV disease

October 25, 2023
Radionuclide Therapy Tops AR-Pathway Inhibitor Switch for mCRPC

Time to radiographic progression doubled with 177Lu-PSMA-617

October 25, 2023
New Options Challenge Standard Treatments in EGFR-Mutant NSCLC

Amivantamab-based regimens improved oncologic outcomes, but with more side effects

October 25, 2023